Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine-Reference-Cited by-同舟云学术

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine

Published:2023-12-11 Issue:3 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Bhatla Neerja¹,Muwonge Richard²,Malvi Sylla G.³,Joshi Smita⁴,Poli Usha Rani Reddy⁵,Lucas Eric²,Esmy Pulikkottil O.⁶,Verma Yogesh⁷,Shah Anand⁸,Zomawia Eric⁹,Pimple Sharmila¹⁰,Jayant Kasturi³,Hingmire Sanjay³,Chiwate Aruna³,Vashist Shachi¹,Mishra Gauravi¹⁰,Jadhav Radhika⁴,Siddiqi Maqsood¹¹,Anantharaman Devasena¹²,Panicker Gitika¹³,Butt Julia¹⁴,Sankaran Subha¹²,Kannan Thiraviam Pillai Rameshwari Ammal¹²,Varghese Rintu¹²,Kartha Purnima¹²,Pillai M. Radhakrishna¹²,Waterboer Tim¹⁴,Müller Martin¹⁴,Sehr Peter¹⁵,Unger Elizabeth R.¹³,Sankaranarayanan Rengaswamy¹⁶,Basu Partha²^ORCID

Affiliation:

1. Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India

2. Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France

3. Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, India

4. Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India

5. Public Health Foundation of India, IIPH-H, Hyderabad, India

6. Department of Oncology, Christian Fellowship Community Health Centre, Ambillikai (near Oddanchathram), India

7. Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok, India

8. Gujarat Cancer & Research Institute (GCRI), M.P. Shah Cancer Hospital, Civil Hospital Campus, Ahmedabad, India

9. National Health Mission, Civil Hospital, Aizawl, India

10. Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India

11. Cancer Foundation of India, Kolkata, India

12. Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India

13. National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA

14. Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany

15. EMBL-DKFZ Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany

16. Kerala Operations, Karkinos Healthcare, Ernakulam, India

Funder

Bill & Melinda Gates Foundation

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2289242

Reference18 articles.

1. Human papillomavirus vaccines: WHO position paper (2022 update);World Health Organization;Wkly Epidemiol Rec,2022

2. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study

3. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

4. HPV - immune response to infection and vaccination

5. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity